These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 33337544)

  • 21. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
    Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
    Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; Orlando B; Bonassi S; Torelli P;
    Neurol Ther; 2024 Jun; 13(3):611-624. PubMed ID: 38451463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ; Ong JJY; Sonu SK; Dang J; Ng CC; Herr KJ; Bose R; Jion YI
    Headache; 2024; 64(7):810-824. PubMed ID: 38785386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
    Barbanti P; Egeo G; Aurilia C; Altamura C; d'Onofrio F; Finocchi C; Albanese M; Aguggia M; Rao R; Zucco M; Frediani F; Filippi M; Messina R; Cevoli S; Carnevale A; Fiorentini G; Messina S; Bono F; Torelli P; Proietti S; Bonassi S; Vernieri F;
    J Headache Pain; 2022 Nov; 23(1):138. PubMed ID: 36316648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H; Schlegel E; Jaeger K; Ortler S; Leist L
    J Headache Pain; 2024 Sep; 25(1):157. PubMed ID: 39322961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erenumab in Chronic Migraine: An Australian Experience.
    Cheng S; Jenkins B; Limberg N; Hutton E
    Headache; 2020 Nov; 60(10):2555-2562. PubMed ID: 32990364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erenumab for episodic migraine prophylaxis.
    Overeem LH; Neeb L; Reuter U
    Expert Rev Neurother; 2019 Aug; 19(8):751-757. PubMed ID: 30614741
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
    Ornello R; Baraldi C; Guerzoni S; Lambru G; Andreou AP; Raffaelli B; Gendolla A; Barbanti P; Aurilia C; Egeo G; Cevoli S; Favoni V; Vernieri F; Altamura C; Russo A; Silvestro M; Valle ED; Mancioli A; Ranieri A; Alfieri G; Latysheva N; Filatova E; Talbot J; Cheng S; Holle D; Scheffler A; Nežádal T; Čtrnáctá D; Šípková J; Matoušová Z; Casalena A; Maddestra M; Viola S; Affaitati G; Giamberardino MA; Pistoia F; Reuter U; Sacco S
    J Headache Pain; 2022 Mar; 23(1):38. PubMed ID: 35305579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
    J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
    Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
    Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
    Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.
    Yiangou A; Mitchell JL; Fisher C; Edwards J; Vijay V; Alimajstorovic Z; Grech O; Lavery GG; Mollan SP; Sinclair AJ
    Headache; 2021 Jan; 61(1):157-169. PubMed ID: 33316102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
    Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
    Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
    Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
    J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
    Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M
    Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.